NERV
Price
$2.59
Change
-$0.00 (-0.00%)
Updated
Oct 3 closing price
31 days until earnings call
SYRE
Price
$29.09
Change
+$0.72 (+2.54%)
Updated
Oct 4, 10:23 AM (EDT)
34 days until earnings call
Ad is loading...

NERV vs SYRE

Header iconNERV vs SYRE Comparison
Open Charts NERV vs SYREBanner chart's image
Minerva Neurosciences
Price$2.59
Change-$0.00 (-0.00%)
Volume$11.77K
CapitalizationN/A
Spyre Therapeutics
Price$29.09
Change+$0.72 (+2.54%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
NERV vs SYRE Comparison Chart
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NERV vs. SYRE commentary
Oct 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a StrongBuy and SYRE is a StrongBuy.

COMPARISON
Comparison
Oct 04, 2024
Stock price -- (NERV: $2.59 vs. SYRE: $28.37)
Brand notoriety: NERV and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 73% vs. SYRE: 39%
Market capitalization -- NERV: $18.57M vs. SYRE: $1.45B
NERV [@Biotechnology] is valued at $18.57M. SYRE’s [@Biotechnology] market capitalization is $1.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • NERV’s TA Score: 3 bullish, 5 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than NERV.

Price Growth

NERV (@Biotechnology) experienced а -4.78% price change this week, while SYRE (@Biotechnology) price change was -2.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.51%. For the same industry, the average monthly price growth was +3.11%, and the average quarterly price growth was -5.53%.

Reported Earning Dates

NERV is expected to report earnings on Nov 04, 2024.

SYRE is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+3.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.45B) has a higher market cap than NERV($18.6M). SYRE YTD gains are higher at: 31.831 vs. NERV (-57.886). NERV has higher annual earnings (EBITDA): -24.78M vs. SYRE (-172.92M). SYRE has more cash in the bank: 426M vs. NERV (30.9M). NERV (0) and SYRE (0) have identical debt. NERV (0) and SYRE (0) have equivalent revenues.
NERVSYRENERV / SYRE
Capitalization18.6M1.45B1%
EBITDA-24.78M-172.92M14%
Gain YTD-57.88631.831-182%
P/E RatioN/A2.70-
Revenue00-
Total Cash30.9M426M7%
Total Debt00-
FUNDAMENTALS RATINGS
NERV vs SYRE: Fundamental Ratings
NERV
SYRE
OUTLOOK RATING
1..100
7264
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6343
P/E GROWTH RATING
1..100
9948
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (56) in the Biotechnology industry is in the same range as SYRE (80) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to SYRE’s over the last 12 months.

NERV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to SYRE’s over the last 12 months.

NERV's SMR Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that NERV’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as NERV (63) in the Biotechnology industry. This means that SYRE’s stock grew similarly to NERV’s over the last 12 months.

SYRE's P/E Growth Rating (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for NERV (99) in the Biotechnology industry. This means that SYRE’s stock grew somewhat faster than NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NERVSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 22 days ago
79%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
NERV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRNEX41.810.24
+0.58%
T. Rowe Price New Era I
LFGFX31.120.14
+0.45%
Lord Abbett Focused Growth F
PAULX43.02-0.10
-0.23%
T. Rowe Price US Large-Cap Core Adv
SESLX30.70-0.08
-0.26%
1919 Socially Responsive Balanced C
SNIEX22.74-0.20
-0.87%
BNY Mellon International Equity I

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with SYRE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-4.08%
SYRE - NERV
35%
Loosely correlated
+2.49%
MIST - NERV
27%
Poorly correlated
N/A
OCUP - NERV
27%
Poorly correlated
-3.01%
SWTX - NERV
26%
Poorly correlated
-3.05%
ATOS - NERV
24%
Poorly correlated
-4.08%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ACIU. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ACIU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+2.49%
ACIU - SYRE
51%
Loosely correlated
-2.59%
SNPX - SYRE
47%
Loosely correlated
-3.00%
PMN - SYRE
44%
Loosely correlated
-9.76%
GOSS - SYRE
41%
Loosely correlated
-3.81%
MLTX - SYRE
41%
Loosely correlated
+0.35%
More